FY2025 Earnings Forecast for Qiagen Issued By Zacks Research

Qiagen N.V. (NYSE:QGEN) – Research analysts at Zacks Research increased their FY2025 earnings per share (EPS) estimates for Qiagen in a research report issued on Tuesday, November 25th. Zacks Research analyst Team now expects that the company will post earnings per share of $2.35 for the year, up from their prior forecast of $2.34. The consensus estimate for Qiagen’s current full-year earnings is $2.26 per share. Zacks Research also issued estimates for Qiagen’s Q1 2026 earnings at $0.58 EPS, Q2 2026 earnings at $0.63 EPS, Q3 2026 earnings at $0.64 EPS, Q4 2026 earnings at $0.62 EPS, FY2026 earnings at $2.48 EPS, Q1 2027 earnings at $0.64 EPS, Q2 2027 earnings at $0.67 EPS, Q3 2027 earnings at $0.70 EPS and FY2027 earnings at $2.73 EPS.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.03. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The company had revenue of $532.58 million for the quarter, compared to analyst estimates of $525.68 million. During the same period last year, the company posted $0.57 earnings per share. Qiagen’s revenue was up 6.2% compared to the same quarter last year.

Other research analysts have also issued reports about the company. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a report on Tuesday. Cowen restated a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. Barclays set a $53.00 price objective on shares of Qiagen and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. UBS Group boosted their target price on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Finally, Wall Street Zen raised shares of Qiagen from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Three research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Qiagen currently has a consensus rating of “Hold” and a consensus target price of $49.69.

Qiagen Stock Performance

QGEN opened at $48.14 on Wednesday. The company has a market cap of $10.70 billion, a P/E ratio of 28.44, a price-to-earnings-growth ratio of 2.48 and a beta of 0.64. Qiagen has a 52-week low of $37.63 and a 52-week high of $51.88. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The firm’s 50-day moving average price is $46.20 and its 200-day moving average price is $46.76.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Amalgamated Bank raised its position in shares of Qiagen by 1.8% in the 2nd quarter. Amalgamated Bank now owns 11,751 shares of the company’s stock valued at $565,000 after purchasing an additional 209 shares in the last quarter. Atria Investments Inc grew its position in shares of Qiagen by 2.9% during the second quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock worth $369,000 after buying an additional 218 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its stake in shares of Qiagen by 9.4% in the second quarter. ANTIPODES PARTNERS Ltd now owns 2,566 shares of the company’s stock worth $123,000 after buying an additional 221 shares during the last quarter. Yousif Capital Management LLC raised its holdings in Qiagen by 3.7% in the second quarter. Yousif Capital Management LLC now owns 6,257 shares of the company’s stock valued at $301,000 after acquiring an additional 222 shares in the last quarter. Finally, Johnson Investment Counsel Inc. raised its holdings in Qiagen by 0.4% in the third quarter. Johnson Investment Counsel Inc. now owns 57,359 shares of the company’s stock valued at $2,563,000 after acquiring an additional 240 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.